Protocol Deviations Listing in Clinical Study Report
ICH E3 appendix 16.2.2 identifies a patient-level protocol-deviations listing, while the E3 Q&A clarifies the meaning of protocol deviation and important protocol deviation. This appendix-level listing is distinct from a general protocol-deviations narrative section, and classification should follow the study’s applicable definitions rather than an invented universal threshold.
ReviewedEvidence2 sourcesSectionWriting & Style
Quick answer
The Protocol Deviations Listing records subject-level departures needed to support the CSR’s account of important deviations and their possible effect on data or participant protection.
Key details
Core IssueICH E3 appendix 16.2.2 identifies a patient-level protocol-deviations listing, while the E3 Q&A clarifies the meaning of protocol deviation and important protocol deviation.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This appendix-level listing is distinct from a general protocol-deviations narrative section, and classification should follow the study’s applicable definitions rather than an invented universal threshold.
Further guidance
Content
Make the subject, deviation, and relevant classification or consequence clear enough to reconcile the listing with the core report’s summary of important protocol deviations.
Purpose
The Protocol Deviations Listing records subject-level departures needed to support the CSR’s account of important deviations and their possible effect on data or participant protection.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 appendix 16.2.1 identifies a patient-level listing for discontinued patients as part of the clinical study report’s individual-patient data appendices. The exact categories and reasons should follow the study protocol and applicable submission conventions; this page does not impose one universal discontinuation taxonomy.
ICH E3 appendix 16.2.6 designates individual efficacy response data as a patient-level listing in the clinical study report supporting material. This is a patient-level listing function, not a substitute for aggregate efficacy tables, statistical analyses, or the broader individual-patient-data appendix overview.
ICH E3 appendix 16.2.8 addresses listings of individual laboratory measurements by patient when such listings are required by regulatory authorities. ICH E3 makes these patient-level listings conditional on regulatory requirements; this page does not imply that every CSR must include the same laboratory appendix.
ICH E3 appendix 16.1.6 calls for a listing of subjects who received specific investigational-product test-drug batches when more than one batch was used. This appendix is conditional on the use of more than one relevant batch and is distinct from broader investigational-product accountability, dose, and exposure narratives.
ICH E3 appendix 16.1.1 places the protocol and protocol amendments among the study-information appendices supporting a clinical study report. This page is about the ICH E3 CSR appendix function; it is distinct from general advice on how a protocol itself should document or justify amendments.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
